Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank

[1] Younossi Z(2018)Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Nat Rev Gastroenterol Hepatol 15 11-910

[2] Yki-Järvinen H(2014)Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome Lancet Diabetes Endocrinol 2 901-58

[3] Kesiraju S(2014)New onset of diabetes after transplantation—an overview of epidemiology, mechanism of development and diagnosis Transpl Immunol 30 52-555

[4] Paritala P(2015)Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States Gastroenterology 148 547-357

[5] Ch UMR(2018)The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases Hepatology 67 328-972

[6] Sahariah S(2020)Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis Hepatol Commun 4 953-981

[7] Wong RJ(2019)Lean non-alcoholic fatty liver disease Clin Nutr 38 975-3573

[8] Chalasani N(2017)Characterisation of liver fat in the UK Biobank cohort PLoS ONE 12 e0172921-1359

[9] Young S(2019)Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis Eur Radiol 29 3564-1611

[10] Wang AY(2018)Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis Hepatology 67 1348-346

[1] Younossi Z(2018)Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Nat Rev Gastroenterol Hepatol 15 11-910

[2] Yki-Järvinen H(2014)Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome Lancet Diabetes Endocrinol 2 901-58

[3] Kesiraju S(2014)New onset of diabetes after transplantation—an overview of epidemiology, mechanism of development and diagnosis Transpl Immunol 30 52-555

[4] Paritala P(2015)Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States Gastroenterology 148 547-357

[5] Ch UMR(2018)The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases Hepatology 67 328-972

[6] Sahariah S(2020)Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis Hepatol Commun 4 953-981

[7] Wong RJ(2019)Lean non-alcoholic fatty liver disease Clin Nutr 38 975-3573

[8] Chalasani N(2017)Characterisation of liver fat in the UK Biobank cohort PLoS ONE 12 e0172921-1359

[9] Young S(2019)Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis Eur Radiol 29 3564-1611

[10] Wang AY(2018)Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis Hepatology 67 1348-346